Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Optical Coherence Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00581503
• Other study ID #: 20064981
• Status: Withdrawn
• Start date: March 2007
• Est. completion date: July 2018

Study information

• Verified date: October 2022
• Source: University of California, Irvine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study has been designed to utilize already obtained biopsy specimens for investigation of the utility of a new, non-invasive optical diagnostic technique. The study will allow a careful correlation between the Optical coherence tomography findings and conventional histology.

Description:

Optical coherence tomography is a non-invasive diagnostic technique that can provide information about tissue abnormalities, change in structure of an organ. This technique uses a near-infrared diode to emit light that can produce images of the specimen under investigation without causing damage or alterations.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2018
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult 18 years and older

• Having procedure of endobronchial, transbronchial, and / or pleural biopsy

Exclusion Criteria:

• Currently participating in any other investigational drug or device evaluation.

• Currently taking drugs that are sensitive to light.

Related Conditions & MeSH terms

• Lung Cancer
• Pleural Cancer
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• diagnostic
oct imaging

Locations

Country	Name	City	State
United States	Pulmonary and Critical Care Medicine, UCI Medical Center	Orange	California
United States	Urology department, UCI Medical Center	Orange	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, Irvine	Beckman Laser Institute University of California Irvine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathology results.		30 minutes